公开(公告)号：US12123043B2

公开(公告)日：2024-10-22

申请号：US16934925

申请日：2020-07-21

申请人： Merus N.V.

发明人： Cornelis Adriaan De Kruif ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC分类号： C12N15/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  C12P21/00 ,  A61K39/00

CPC分类号： C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

摘要： The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US20240228961A9

公开(公告)日：2024-07-11

申请号：US18373569

申请日：2023-09-27

申请人： Wisconsin Alumni Research Foundation

发明人： Nathan Mark SHERER ,  Ryan Thomas BEHRENS

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61K38/16 ,  C07K14/47 ,  C07K14/705 ,  C12N15/00 ,  C12N15/09

CPC分类号： C12N5/0637 ,  A61K35/17 ,  A61K38/16 ,  C07K14/4705 ,  C07K14/705 ,  C12N15/00 ,  C12N15/09 ,  A61K38/00

摘要： Genetically modified CCNT1 and XPO1 genes encoding proteins that inhibit virus infection in cells. The genetically modified CCNT1 gene encodes a protein with a C261Y substitution with respect to the human CCNT1 protein. The genetically modified XPO1 gene encodes a protein with P411T, M412V, and/or F414S substitutions with respect to the human XPO1 protein. The genetically modified CCNT1 and XPO1 genes can be introduced in cells. The cells comprising the genetically modified CCNT1 and XPO1 genes can be introduced in a subject with a virus infection to treat the infection.

公开(公告)号：US12031149B2

公开(公告)日：2024-07-09

申请号：US16833119

申请日：2020-03-27

申请人： EmendoBio Inc.

发明人： David Baram ,  Lior Izhar ,  Asael Herman ,  Rafi Emmanuel ,  Michal Golan Mashiach ,  Joseph Georgeson

IPC分类号： C12N15/00 ,  A61K48/00 ,  A61P37/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

CPC分类号： C12N15/907 ,  A61K48/00 ,  A61P37/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/111 ,  C12N15/1136 ,  C12N2310/20 ,  C12N2800/80

摘要： RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6601 and compositions, methods, and uses thereof.

公开(公告)号：US12018304B2

公开(公告)日：2024-06-25

申请号：US17386204

申请日：2021-07-27

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Michael Shareef Siddiqui ,  Christina D. Smolke

IPC分类号： C12P17/12 ,  C12N1/20 ,  C12N9/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/10 ,  C12N9/14 ,  C12N9/88 ,  C12N9/90 ,  C12N15/00 ,  C12N15/52 ,  C12P7/24 ,  C12P13/00 ,  C12P13/22

CPC分类号： C12P17/12 ,  C12N9/0006 ,  C12N9/0008 ,  C12N9/0071 ,  C12N9/1085 ,  C12N9/90 ,  C12N15/52 ,  C12P7/24 ,  C12P13/001 ,  C12P13/225

摘要： Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAS) precursors, such as norcoclaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.

公开(公告)号：US12016885B2

公开(公告)日：2024-06-25

申请号：US17290608

申请日：2019-11-06

申请人： ALSaTECH, Inc.

发明人： Claude Nicolau ,  Claudine Kieda ,  Reynald Thinard ,  Ruth Greferath ,  Melanie Chevalier

IPC分类号： A61K35/12 ,  A61K35/44 ,  A61K39/00 ,  A61K39/395 ,  A61P25/00 ,  A61P25/28 ,  C07K16/00 ,  C07K16/18 ,  C12N5/00 ,  C12N5/07 ,  C12N5/071 ,  C12N15/00 ,  C12N15/09 ,  C12N15/85

CPC分类号： A61K35/44 ,  C07K16/18 ,  C12N5/0691 ,  C12N15/85 ,  C07K2317/50 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/02

摘要： The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.

公开(公告)号：US12011479B2

公开(公告)日：2024-06-18

申请号：US17518268

申请日：2021-11-03

申请人： Mayo Foundation for Medical Education and Research

发明人： Miguel A. Munoz Alia ,  Stephen James Russell

IPC分类号： C12N7/00 ,  A61K39/165 ,  C12N7/01 ,  C12N15/00 ,  C12N15/86 ,  C12N15/861 ,  A61K39/00

CPC分类号： A61K39/165 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/55 ,  C12N2710/10021 ,  C12N2760/18421 ,  C12N2760/18422 ,  C12N2760/18434

摘要： This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

公开(公告)号：US11998016B2

公开(公告)日：2024-06-04

申请号：US17233732

申请日：2021-04-19

申请人： Institute of Plant Protection, Henan Academy of Agricultural Sciences

发明人： Fei Xu ,  Yuli Song ,  Junmei Wang ,  Jiaojiao Zhang ,  Zixing Han ,  Yahong Li ,  Ruijie Shi ,  Lijuan Li ,  Lulu Liu

IPC分类号： A01N63/30 ,  A01N25/04 ,  C12N15/00

CPC分类号： A01N63/30 ,  A01N25/04 ,  C12N15/00

摘要： The present disclosure provides use of a Chaetomium globosum strain in controlling Fusarium crown rot (FCR) of wheat. The C. globosum strain under the deposit designation of 12XP1-2-3 is deposited at China General Microbiological Culture Collection Center (CGMCC) on Jan. 23, 2019 with an accession number of CGMCC No. 17183. Field experiments conclude that coating of wheat seeds with Chaetomium globosum strain 12XP1-2-3 can reduce diseased stem rate, disease rating, and disease index by 19.0%-41.3%, 43.7%, and 4.7%-45.4%, respectively.

公开(公告)号：US20240174748A1

公开(公告)日：2024-05-30

申请号：US18432126

申请日：2024-02-05

申请人： INNATE PHARMA

发明人： LAURENT GAUTHIER ,  NADIA ANCERIZ ,  ARIANE MOREL ,  BENJAMIN ROSSI

IPC分类号： C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66

CPC分类号： C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/468 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C12N2511/00 ,  C12N2523/00

摘要： The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20240158757A1

公开(公告)日：2024-05-16

申请号：US18352622

申请日：2023-07-14

申请人： Cedars-Sinai Medical Center

发明人： Dhruv Sareen ,  Loren Ornelas ,  Robert Barrett

IPC分类号： C12N5/074 ,  A61K35/17 ,  C12N15/00 ,  C12N15/86 ,  A61K35/12

CPC分类号： C12N5/0696 ,  A61K35/17 ,  C12N15/00 ,  C12N15/86 ,  A61K2035/124 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/16 ,  C12N2501/235 ,  C12N2501/48 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/11

摘要： Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.

公开(公告)号：US11976282B2

公开(公告)日：2024-05-07

申请号：US16909755

申请日：2020-06-23

申请人： QATAR UNIVERSITY

发明人： Mohamed Elrayess ,  Layla Almansoori

IPC分类号： C12N15/00 ,  A61K9/00 ,  A61P3/10 ,  C12N15/113

CPC分类号： C12N15/1138 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61P3/10

摘要： Methods and compositions using dnayzme-based GATA3 inhibitors for the treatment of insulin resistance and Type II diabetes, for the stimulation of adipogenesis in vivo, and for the promotion of fat redistribution are disclosed.